Venetoclax
Showing 376 - 400 of 485
AL Amyloidosis Trial in Boston (Venetoclax, Dexamethasone)
Terminated
- AL Amyloidosis
- Venetoclax
- Dexamethasone
-
Boston, MassachusettsTufts Medical Center
Aug 19, 2020
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising
Not yet recruiting
- Acute Myeloid Leukemia
- +4 more
- Azacitidine
- +6 more
- (no location specified)
Nov 8, 2022
Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Worldwide (ibrutinib, venetoclax, Placebo)
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Alvocidib Hydrochloride, Decitabine,
Withdrawn
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Alvocidib Hydrochloride
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Nov 9, 2020
Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia Trial in United States (Ibrutinib, Rituximab, Venetoclax)
Suspended
- Lymphoplasmacytic Lymphoma
- Waldenstrom Macroglobulinemia
- Ibrutinib
- +2 more
-
Centralia, Illinois
- +73 more
Jul 27, 2022
Myeloid Malignancies Trial in Australia, United Kingdom, United States (Magrolimab, Azacitidine, Venetoclax)
Recruiting
- Myeloid Malignancies
- Magrolimab
- +6 more
-
Birmingham, Alabama
- +12 more
Apr 6, 2022
Chronic Lymphocytic Leukemia Trial in Worldwide (Fludarabine, Cyclophosphamide, Rituximab)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Fludarabine
- +6 more
-
Wien, Austria
- +160 more
Sep 29, 2021
AML, Adult, MDS Trial in Lørenskog (Standard therapy, Precision therapy)
Recruiting
- AML, Adult
- MDS
- Standard therapy
- Precision therapy
-
Lørenskog, NorwayAkershus Universitetssykehus
Aug 23, 2021
Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia Trial in Columbus (drug, biological, other)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Bcl-2 Inhibitor GDC-0199
- +5 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Oct 29, 2021
Chronic Lymphoid Leukemia Trial in Worldwide (Ibrutinib, Venetoclax, Obinutuzumab)
Recruiting
- Chronic Lymphoid Leukemia
- Ibrutinib
- +2 more
-
Graz, Austria
- +180 more
Jan 21, 2022
Blastic Plasmacytoid Dendritic Cell Tumor Trial in Houston (Cyclophosphamide, Cytarabine, Dexamethasone)
Recruiting
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Cyclophosphamide
- +11 more
-
Houston, TexasM D Anderson Cancer Center
Nov 30, 2021
Chronic Lymphocytic Leukemia Trial in Worldwide (Acalabrutinib, Venetoclax, Chemoimmunotherapy)
Recruiting
- Chronic Lymphocytic Leukemia
- Acalabrutinib
- +3 more
-
Fountain Valley, California
- +201 more
Jan 16, 2023
Chronic Lymphocytic Leukemia Trial in France, Germany, United States (Bendamustine, Obinutuzumab, Rituximab)
Completed
- Chronic Lymphocytic Leukemia
- Bendamustine
- +3 more
-
La Jolla, California
- +11 more
Oct 12, 2020
Chronic Myeloid Leukemia Trial in Italy (Venetoclax, Rituximab)
Active, not recruiting
- Chronic Myeloid Leukemia
- Venetoclax
- Rituximab
-
Alessandria, Italy
- +30 more
Jan 3, 2022
Acute Myeloid Leukemia With FLT3/ITD Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Leukemia Trial in Houston
Recruiting
- Acute Myeloid Leukemia With FLT3/ITD Mutation
- +2 more
- Quizartinib
- Venetoclax
-
Houston, TexasM D Anderson Cancer Center
May 13, 2020
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Indianapolis, Rochester, Wauwatosa (Bortezomib,
Withdrawn
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Indianapolis, Indiana
- +2 more
Sep 29, 2020
Relapsed or Refractory DLBCL Trial in United States (Selinexor, Rituximab, Bendamustine)
Suspended
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Selinexor
- +9 more
-
Tucson, Arizona
- +17 more
Jan 24, 2023
Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial (Azacitidine, Biospecimen Collection, Bone Marrow Aspiration)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Azacitidine
- +10 more
- (no location specified)
Jan 13, 2023